Terms: = Germ cell tumor AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
380 results:
1. EPIC-0628 abrogates HOTAIR/ezh2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.
Yang E; Hong B; Wang Y; Wang Q; Zhao J; Cui X; Wu Y; Yang S; Su D; Liu X; Kang C
Cancer Lett; 2024 Apr; 588():216812. PubMed ID: 38490327
[TBL] [Abstract] [Full Text] [Related]
2. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma cells.
Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
[TBL] [Abstract] [Full Text] [Related]
3. Mi-2β promotes immune evasion in melanoma by activating ezh2 methylation.
Li C; Wang Z; Yao L; Lin X; Jian Y; Li Y; Zhang J; Shao J; Tran PD; Hagman JR; Cao M; Cong Y; Li HY; Goding CR; Xu ZX; Liao X; Miao X; Cui R
Nat Commun; 2024 Mar; 15(1):2163. PubMed ID: 38461299
[TBL] [Abstract] [Full Text] [Related]
4. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract] [Full Text] [Related]
5. Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
6. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract] [Full Text] [Related]
7. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
[TBL] [Abstract] [Full Text] [Related]
8. Combined Inhibition of ezh2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract] [Full Text] [Related]
9. Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germline
Tibout P; Livingston J; Kanwar N; Yuki KE; Shlien A; Ngan B; Irwin MS; Morgenstern DA; Hitzler J; Villani A; Cohen-Gogo S
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37932047
[TBL] [Abstract] [Full Text] [Related]
10. SUZ12 inhibition attenuates cell proliferation of glioblastoma via post-translational regulation of CDKN1B.
Kim S; Jo S; Paek SH; Kang SS; Chung H
Genes Genomics; 2023 Dec; 45(12):1623-1632. PubMed ID: 37856053
[TBL] [Abstract] [Full Text] [Related]
11. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and ezh2 and N-Myc Downregulation.
Le Clorennec C; Lee K; Huo Y; Zage PE
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
[TBL] [Abstract] [Full Text] [Related]
12. Ribosomal S6 protein kinase 4 promotes resistance to ezh2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract] [Full Text] [Related]
13. Targeting ezh2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract] [Full Text] [Related]
14. ezh2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
[TBL] [Abstract] [Full Text] [Related]
15. 3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
Hosokawa M; Tetsumoto S; Yasui M; Kono Y; Ogawara KI
Biochem Biophys Res Commun; 2023 Oct; 677():26-30. PubMed ID: 37542772
[TBL] [Abstract] [Full Text] [Related]
16. Review: Targeting ezh2 in neuroblastoma.
Gao J; Fosbrook C; Gibson J; Underwood TJ; Gray JC; Walters ZS
Cancer Treat Rev; 2023 Sep; 119():102600. PubMed ID: 37467626
[TBL] [Abstract] [Full Text] [Related]
17. Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma.
Li Y; Gao Z; Wang Y; Pang B; Zhang B; Hu R; Wang Y; Liu C; Zhang X; Yang J; Mei M; Wang Y; Zhou X; Li M; Ren Y
Nat Commun; 2023 Jul; 14(1):4062. PubMed ID: 37429858
[TBL] [Abstract] [Full Text] [Related]
18. Epigenetically modified AP-2α by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression.
Long S; Huang G; Ouyang M; Xiao K; Zhou H; Hou A; Li Z; Zhong Z; Zhong D; Wang Q; Xiang S; Ding X
Cell Death Dis; 2023 Jun; 14(6):365. PubMed ID: 37330579
[TBL] [Abstract] [Full Text] [Related]
19. ezh2 Expression in Retinoblastoma: A Potential Therapeutic Target.
Lin Z; Tang L; Chen S; Zhang W; Lin J; Gao H; Zhang P
Ophthalmic Res; 2023; 66(1):1014-1019. PubMed ID: 37311441
[TBL] [Abstract] [Full Text] [Related]
20. The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics.
Deng Z; Richardson DR
Pharmacol Rev; 2023 Sep; 75(5):1007-1035. PubMed ID: 37280098
[TBL] [Abstract] [Full Text] [Related]
[Next]
